The different facets of dyslipidemia and hypertension in atherosclerosis

Current Atherosclerosis Reports

Volumn 18, Issue 12, 2016, Pages

  Hurtubise, Jessica ^a   McLellan, Krystie ^a   Durr, Kevin ^a   Onasanya, Oluwadara ^a   Nwabuko, Daniel ^a   Ndisang, Joseph Fomusi ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Dyslipidemia; Endothelial dysfunction; High density lipoprotein; Hypertension; Inflammation; Low density lipoprotein; Oxidative stress

Indexed keywords

ALCOHOL; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; LIPOPROTEIN;

ALCOHOL CONSUMPTION; ANGIOGRAPHY; ANGIOPLASTY; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; DIAGNOSTIC IMAGING; DIET; DISEASE ASSOCIATION; DYSLIPIDEMIA; EXERCISE; FEEDING BEHAVIOR; HUMAN; HYPERTENSION; LIFESTYLE; MEDICATION THERAPY MANAGEMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING; ANIMAL; COMPLICATION; INFLAMMATION; METABOLISM;

ANIMALS; ATHEROSCLEROSIS; DYSLIPIDEMIAS; HUMANS; HYPERTENSION; INFLAMMATION; LIPOPROTEINS; OXIDATIVE STRESS;

EID: 84995550206     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-016-0632-z     Document Type: Article

References (98)

1. Selvin E, Coresh J, Shahar E, Zhang L, Steffes M, Sharrett AR. Glycaemia (haemoglobin A1c) and incident ischaemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. The Lancet Neurology. 2005;4(12):821-6.
2. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917): 868-74.
3. Zarins CK, Giddens DP, Bharadvaj BK, Sottiurai VS, Mabon RF, Glagov S. Carotid bifurcation atherosclerosis. Quantitative correlation of plaque localizationwith flowvelocity profiles and wall shear stress. Circ Res. 1983;53(4):502-14.
4. Liu C, Guo Q, Lu M, Li Y. An experimental study on amelioration of dyslipidemia-induced atherosclesis by Clematichinenoside through regulating Peroxisome proliferator-activated receptor-alpha mediated apolipoprotein A-I, A-II and C-III. Eur J Pharmacol. 2015;761:362-74.
5. Ambale Venkatesh B, Volpe GJ, Donekal S, et al. Association of longitudinal changes in left ventricular structure and function with myocardial fibrosis: the Multi-Ethnic Study of Atherosclerosis study. Hypertension. 2014;64(3):508-15.
6. Cochain C, Zernecke A. Macrophages and immune cells in atherosclerosis: recent advances and novel concepts. Basic Res Cardiol. 2015;110(4):34.
7. Atabek ME, Akyurek N, Eklioglu BS, Alp H. Impaired systolic blood dipping and nocturnal hypertension: an independent predictor of carotid intima-media thickness in type 1 diabetic patients. J Diabetes Complicat. 2014;28(1):51-5.
8. Pan WH, Bai CH, Chen JR, Chiu HC. Associations between carotid atherosclerosis and high factor VIII activity, dyslipidemia, and hypertension. Stroke. 1997;28(1):88-94.
9. Reina SA, Llabre MM, Allison MA, et al. HDL cholesterol and stroke risk: the multi-ethnic study of atherosclerosis. Atherosclerosis. 2015;243(1):314-9.
10. Rozanski A, Gransar H, Shaw L, et al. Comparison of the atherosclerotic burden among asymptomatic patients vs matched volunteers. J Nucl Cardiol. 2011;18(2):291-8. This paper underscores problems associated with diagnosis of atherosclerosis, especially in asymptomatic patients. By using coronary artery calcium (CAC) scanning, the authors showed that asymptomatic patients referred for cardiac stress testing manifested some degree of atherosclerosis.
11. Duman S. Rational approaches to the treatment of hypertension: diet. Kidney Int Suppl. 2013;3(4):343-5.
12. Kim HY, Choi JH. How to utilize coronary computed tomography angiography in the treatment of coronary artery disease. J Cardiovasc Ultrason. 2015;23(4):204-8.
13. Niccoli G, Cin D, Scalone G, et al. Lipoprotein (a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease. Atherosclerosis. 2016;246:214-20.
14. Chung DW, Chen J, Ling M, et al. High density lipoprotein modulates thrombosis by preventing von Willebrand factor selfassociation and subsequent platelet adhesion. Blood. 2016 127: 637-45.
15. Kolski B, Tsimikas S. Emerging therapeutic agents to lower lipoprotein (a) levels. Curr Opin Lipidol. 2012;23(6):560-8.
16. Guerra R, Yu Z, Marcovina S, Peshock R, Cohen JC, Hobbs HH. Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the Dallas Heart Study. Circulation. 2005;111(12):1471-9.
17. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90(1):52-60.
18. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518-28.
19. Arsenault BJ, Boekholdt SM, Dube MP, et al. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet. 2014;7(3):304-10.
20. Utermann G. Genetic architecture and evolution of the lipoprotein(a) trait. Curr Opin Lipidol. 1999;10(2):133-41.
21. Sorokin A, Kotani K. Lipoprotein(a) and arterial stiffness parameters. Pulse. 2015;3(2):148-52. The authors reported a positive association between lipoprotein(a) and arterial stiffness following the measurement of ‘pulse wave velocity’ and ‘cardio-ankle vascular index’, and suggested that lipoprotein(a) could be used a non-invasive bio-marker of atherosclerosis.
22. Sponder M, Fritzer-Szekeres M, Marculescu R, Litschauer B, Strametz-Juranek J. A new coronary artery disease grading system correlates with numerous routine parameters that were associated with atherosclerosis: a grading system for coronary artery disease severity. Vasc Health Risk Manag. 2014;10:641-7.
23. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111(25):3481-8.
24. Moore RD, Jackson JC, Venkatesh SL, Quarfordt SD, Baxter BW. Revisiting the NIH Stroke Scale as a screening tool for proximal vessel occlusion: can advanced imaging be targeted in acute stroke? J NeuroIntervent Surg. 2016. doi:10.1136/neurintsurg-2015-012088.
25. Schainfeld RM. Management of peripheral arterial disease and intermittent claudication. The Journal of the American Board of Family Practice/American Board of Family Practice. 2001;14(6): 443-50.
26. Espinola-Klein C, Rupprecht HJ, Blankenberg S, et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation. 2002;105(1):15-21.
27. Luczak M, Formanowicz D, Marczak L, et al. Deeper insight into chronic kidney disease-related atherosclerosis: comparative proteomic studies of blood plasma using 2DE and mass spectrometry. J Transl Med. 2015;13:20.
28. Schroeder B, Francis G, Leipsic J, Heilbron B, John Mancini GB, Taylor CM. Early atherosclerosis detection in asymptomatic patients: a comparison of carotid ultrasound, coronary artery calcium score, and coronary computed tomography angiography. Can J Cardiol. 2013;29(12):1687-94.
29. Verjans JW, Jaffer FA. Biological imaging of atherosclerosis: moving beyond anatomy. J Cardiovasc Transl Res. 2013;6(5):681-94.
30. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol. 2010;30(7):1282-92.
31. Jaffer FA, Vinegoni C, John MC, et al. Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation. 2008;118(18):1802-9.
32. Gaemperli O, Saraste A, Knuuti J. Cardiac hybrid imaging. Eur Heart J Cardiovasc Imaging. 2012;13(1):51-60.
33. Tarkin JM, Joshi FR, Rudd JH. PET imaging of inflammation in atherosclerosis. Nat Rev Cardiol. 2014;11(8):443-57.
34. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation. 1986;74(6):1399-406.
35. Nissen SE, Yock P. Intravascular ultrasound: novel pathophysiological insights and current clinical applications. Circulation. 2001;103(4):604-16.
36. Safar ME. Arterial aging—hemodynamic changes and therapeutic options. Nat Rev Cardiol. 2010;7(8):442-9.
37. Agbor-Etang BB, Setaro JF. Management of hypertension in patients with ischemic heart disease. Curr Cardiol Rep. 2015;17(12): 119.
38. Silva PM, Cardoso SM, Ferreira AM. Persistent lipid abnormalities in patients with hypertension and dyslipidemia treated with statins: results of the Portuguese hypertensive subpopulation of the Dyslipidemia International Study (DYSIS). Clin Exp Hypertens. 2015;37(2):116-21.
39. Huang Q, Qin L, Dai S, et al. AIP1 suppresses atherosclerosis by limiting hyperlipidemia-induced inflammation and vascular endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2013;33(4): 795-804.
40. Kassan M, Galan M, Partyka M, et al. Endoplasmic reticulum stress is involved in cardiac damage and vascular endothelial dysfunction in hypertensive mice. Arterioscler Thromb Vasc Biol. 2012;32(7): 1652-61.
41. Ndisang JF, Wang R. Novel therapeutic strategies for impaired endothelium-dependent vascular relaxation. Expert Opin Ther Patents. 2002;12(8):1237-47.
42. Ndisang JF, Wang R. Alterations in heme oxygenase/carbon monoxide system in pulmonary arteries in hypertension. Exp BiolMed. 2003;228(5):557-63.
43. Ndisang JF, Wang R. Age-related alterations in soluble guanylyl cyclase and cGMP pathway in spontaneously hypertensive rats. J Hypertens. 2003;21(6):1117-24.
44. Ndisang JF, Jadhav A. Heme-arginate suppresses phospholipase C and oxidative stress in the mesenteric arterioles ofmineralcorticoidinduced hypertensive rats. Hypertens Res. 2010;33(4):338-47.
45. Yang HY, Bian YF, Zhang HP, et al. LOX1 is implicated in oxidized low-density lipoprotein-induced oxidative stress of macrophages in atherosclerosis. Mol Med Rep. 2015;12(4):5335-41.
46. Peire MA, Puig-Parellada P. Oxygen-free radicals and nitric oxide are involved in the thrombus growth produced by iontophoresis of ADP. Pharmacol Res. 1998;38(5):353-6.
47. Droge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82(1):47-95.
48. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135-43.
49. Endtmann C, Ebrahimian T, Czech T, et al. Angiotensin II impairs endothelial progenitor cell number and function in vitro and in vivo: implications for vascular regeneration. Hypertension. 2011;58(3): 394-403.
50. Landmesser U, Drexler H. The clinical significance of endothelial dysfunction. Curr Opin Cardiol. 2005;20(6):547-51.
51. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering—are they clinically relevant? Eur Heart J. 2003;24(3):225-48.
52. Cholesterol Treatment Trialists C, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81.
53. de Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy. 2004;24(5):584-91.
54. Nickenig G, Stablein A, Wassmann S, Wyen C, Muller C, Bohm M. Acute effects of ACE inhibition on coronary endothelial dysfunction. J Renin Angiotensin Aldosterone Syst. 2000;1(4):361-4.
55. Yamamoto K, Ozaki H, Takayasu K, et al. The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. Hypertens Res. 2011;34(3):325-30.
56. Napoli C, Bruzzese G, Ignarro LJ, et al.: Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. American Heart Journal 2008, 156(6):1154 e1151-1158.
57. Sonoda M, Aoyagi T, Takenaka K, Uno K, Nagai R. A one-year study of the antiatherosclerotic effect of the angiotensin-II receptor blocker losartan in hypertensive patients. A comparison with angiotension-converting enzyme inhibitors. Int Heart J. 2008;49(1):95-103.
58. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 2000;101(13): 1586-93.
59. Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131(5):495-502.
60. Siracuse JJ, Giles KA, Pomposelli FB, et al. Results for primary bypass versus primary angioplasty/stent for intermittent claudication due to superficial femoral artery occlusive disease. J Vasc Surg. 2012;55(4):1001-7.
61. McTaggart RA, Marks MP. The case for angioplasty in patients with symptomatic intracranial atherosclerosis. Front Neurol. 2014;5:36. This article describes the role of endovascular treatment of intracranial atherosclerotic disease with primary intracranial angioplasty in selected patients.
62. Baur LA, Hazelton B, Shrewsbury VA. Assessment and management of obesity in childhood and adolescence. Nat Rev Gastroenterol Hepatol. 2011;8(11):635-45.
63. Chen MM, O’Halloran EB, Ippolito JA, Choudhry MA, Kovacs EJ. Alcohol potentiates postburn remote organ damage through shifts in fluid compartments mediated by bradykinin. Shock. 2015;43(1): 80-4.
64. Kumari S, Mittal A, Dabur R. Moderate alcohol consumption in chronic form enhances the synthesis of cholesterol and C-21 steroid hormones, while treatment with Tinospora cordifolia modulate these events in men. Steroids. 2016;114:68-77.
65. Solak ZA, Kabaroglu C, Cok G, et al. Effect of different levels of cigarette smoking on lipid peroxidation, glutathione enzymes and paraoxonase 1 activity in healthy people. Clin Exp Med. 2005;5(3): 99-105.
66. Sotos-Prieto M, Bhupathiraju SN, Mattei J, et al. Changes in diet quality scores and risk of cardiovascular disease among US men and women. Circulation. 2015;132(23):2212-9.
67. Joint WHO/FAO Expert Consultation on Diet NatPoCD: Diet, nutrition and the prevention of chronic diseases. Report of a joint WHO/FAO expert consultation. Geneva, Switzerland 2003, 916: 104-117.
68. Jankovic N, Geelen A, Streppel MT, et al. WHO guidelines for a healthy diet and mortality from cardiovascular disease in European and American elderly: the CHANCES project. Am J Clin Nutr. 2015;102(4):745-56.
69. Ghayur MN, Janssen LJ. A natural way to cardiovascular health. Nat Rev Cardiol. 2010;7(3):1-2.
70. Urpi-Sarda M, Casas R, Chiva-Blanch G, et al. Virgin olive oil and nuts as key foods of theMediterranean diet effects on inflammatory biomarkers related to atherosclerosis. Pharmacol Res. 2012;65(6): 577-83.
71. Hansen D, Dendale P, van Loon LJ, Meeusen R. The impact of training modalities on the clinical benefits of exercise intervention in patients with cardiovascular disease risk or type 2 diabetes mellitus. Sports Med. 2010;40(11):921-40.
72. Lenk K, Uhlemann M, Schuler G, Adams V. Role of endothelial progenitor cells in the beneficial effects of physical exercise on atherosclerosis and coronary artery disease. J Appl Physiol. 2011;111(1):321-8.
73. Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation. 2003;107(24):3109-16.
74. Press V, Freestone I, George CF. Physical activity: the evidence of benefit in the prevention of coronary heart disease. QJM: monthly journal of the Association of Physicians. 2003;96(4):245-51.
75. Ndisang JF, Wang R, Vannacci A, et al. Haeme oxygenase-1 and cardiac anaphylaxis. Br J Pharmacol. 2001;134(8):1689-96.
76. Ndisang JF, Mishra M. The heme oxygenase system selectively suppresses the proinflammatory macrophage m1 phenotype and potentiates insulin signaling in spontaneously hypertensive rats. Am J Hypertens. 2013;26(9):1123-31.
77. Ndisang JF, Chibbar R. Heme oxygenase improves renal function by potentiating podocyte-associated proteins in N omega-nitro-larginine-methyl ester (l-NAME)-induced hypertension. Am J Hypertens. 2015;28(7):930-42.
78. Ndisang JF, Chibbar R, Lane N. Heme oxygenase suppresses markers of heart failure and ameliorates cardiomyopathy in LNAME-induced hypertension. Eur J Pharmacol. 2014;734:23-34.
79. Ndisang JF, Jadhav A. Upregulating the heme oxygenase system suppresses left ventricular hypertrophy in adult spontaneously hypertensive rats for 3 months. J Card Fail. 2009;15(7):616-28.
80. Ndisang JF, Jadhav A. Heme arginate therapy enhanced adiponectin and atrial natriuretic peptide, but abated endothelin-1 with attenuation of kidney histopathological lesions in mineralocorticoid-induced hypertension. J Pharmacol Exp Ther. 2010;334(1):87-98.
81. Ndisang JF, Jadhav A. Hemin therapy suppresses inflammation and retroperitoneal adipocyte hypertrophy to improve glucose metabolism in obese rats co-morbid with insulin-resistant type-2 diabetes. Diabetes Obes Metab. 2013;15(11):1029-39.
82. Ndisang JF, Jadhav A. Hemin therapy improves kidney function in male streptozotocin-induced diabetic rats: role of the heme oxygenase/atrial natriuretic peptide/adiponectin axis. Endocrinology. 2014;155(1):215-29.
83. Ndisang JF, Jadhav A, Mishra M. The heme oxygenase system suppresses perirenal visceral adiposity, abates renal inflammation and ameliorates diabetic nephropathy in Zucker diabetic fatty rats. PLoS One. 2014;9(1), e87936.
84. Ndisang JF, Lane N, Jadhav A. The heme oxygenase system abates hyperglycemia in Zucker diabetic fatty rats by potentiating insulinsensitizing pathways. Endocrinology. 2009;150(5):2098-108.
85. Ndisang JF, Lane N, Jadhav A. Upregulation of the heme oxygenase system ameliorates postprandial and fasting hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab. 2009;296(5): E1029-41.
86. Ndisang JF, Lane N, Syed N, Jadhav A. Up-regulating the heme oxygenase system with hemin improves insulin sensitivity and glucose metabolism in adult spontaneously hypertensive rats. Endocrinology. 2010;151(2):549-60.
87. Jadhav A, Ndisang JF. Treatment with heme arginate alleviates adipose tissue inflammation and improves insulin sensitivity and glucose metabolism in a rat model of Human primary aldosteronism. Free Radic Biol Med. 2012;53(12):2277-86.
88. Jadhav A, Tiwari S, Lee P, Ndisang JF. The heme oxygenase system selectively enhances the anti-inflammatory macrophage-M2 phenotype, reduces pericardial adiposity, and ameliorated cardiac injury in diabetic cardiomyopathy in Zucker diabetic fatty rats. J Pharmacol Exp Ther. 2013;345(2):239-49.
89. Jadhav A, Ndisang JF. Heme arginate suppresses cardiac lesions and hypertrophy in deoxycorticosterone acetate-salt hypertension. Exp Biol Med (Maywood). 2009;234(7):764-78.
90. Tiwari S, Ndisang JF. Heme oxygenase system and hypertension: a comprehensive insight. Curr Pharm Des. 2014;20(9):1354-69.
91. Tiwari S, Ndisang JF. The heme oxygenase system and type-1 diabetes. Curr Pharm Design. 2014;20(9):1328-37.
92. Fantuzzi G, Mazzone T. Adipose tissue and atherosclerosis: exploring the connection. Arterioscler Thromb Vasc Biol. 2007;27(5): 996-1003.
93. Keating ST, Plutzky J, El-Osta A. Epigenetic changes in diabetes and cardiovascular risk. Circ Res. 2016;118(11):1706-22.
94. Kwak BR, Back M, Bochaton-Piallat ML, et al. Biomechanical factors in atherosclerosis: mechanisms and clinical implications. Eur Heart J 2014, 35(43):3013-3020, 3020a-3020d.
95. Kusters DM, Vissers MN, Wiegman A, Kastelein JJ, Hutten BA. Treatment of dyslipidaemia in childhood. Expert Opin Pharmacother. 2010;11(5):739-53.
96. Liu J, Ren Y, Kang L, Zhang L. Overexpression of CCN3 inhibits inflammation and progression of atherosclerosis in apolipoprotein E-deficient mice. PLoS One. 2014;9(4), e94912.
97. Abraham NG, Junge JM, Drummond GS. Translational significance of heme oxygenase in obesity and metabolic syndrome. Trends Pharmacol Sci. 2016;37(1):17-36.
98. Pechlaner R, Willeit P, Summerer M, et al. Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with progressive atherosclerosis and incident cardiovascular disease. Arterioscler Thromb Vasc Biol. 2015;35(1):229-36.